{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:22:08Z","timestamp":1762161728604,"version":"build-2065373602"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cld.2022.06.013","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T08:59:58Z","timestamp":1663059598000},"page":"747-764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel Therapies in Primary Biliary Cholangitis"],"prefix":"10.1016","volume":"26","author":[{"given":"Keri-Ann","family":"Buchanan-Peart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2022.06.013_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2015.07.004","article-title":"The immunogenetics of primary biliary cirrhosis: a comprehensive review","volume":"64","author":"Webb","year":"2015","journal-title":"J\u00a0Autoimmun"},{"issue":"3","key":"10.1016\/j.cld.2022.06.013_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cld.2018.03.003","article-title":"Current treatment options for primary biliary cholangitis","volume":"22","author":"Wong","year":"2018","journal-title":"Clin Liver Dis"},{"issue":"10003","key":"10.1016\/j.cld.2022.06.013_bib3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2022.06.013_bib4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0016-5085(80)90571-5","article-title":"Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients","volume":"78","author":"Christensen","year":"1980","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.013_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1872-034X.2007.00297.x","article-title":"Ursodeoxycholic acid: mechanism of action and novel clinical applications","volume":"38","author":"Ikegami","year":"2008","journal-title":"Hepatol Res"},{"issue":"4","key":"10.1016\/j.cld.2022.06.013_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jceh.2016.10.001","article-title":"Primary biliary cholangitis: disease pathogenesis and implications for established and novel therapeutics","volume":"6","author":"Patel","year":"2016","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.013_bib8","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"29","author":"Poupon","year":"1999","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.013_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MOG.0000000000000708","article-title":"Primary biliary cholangitis: treatment","volume":"37","author":"Cazzagon","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2022.06.013_bib10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2022.06.013_bib11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.cld.2022.06.013_bib12","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep4.1720","article-title":"Impact of obeticholic acid exposure on decompensation and mortality in primary biliary cholangitis and cirrhosis","volume":"5","author":"John","year":"2021","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.cld.2022.06.013_bib13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.31017","article-title":"Liver injury in patients with cholestatic liver disease treated with obeticholic acid","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic acid-a new therapy in PBC and NASH","volume":"133","author":"Chapman","year":"2020","journal-title":"Br Med Bull"},{"issue":"5","key":"10.1016\/j.cld.2022.06.013_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.cld.2022.06.013_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.cld.2022.06.013_bib17","doi-asserted-by":"crossref","first-page":"33453","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.cld.2022.06.013_bib18","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jhep.2017.01.013","article-title":"Steroidal or non-steroidal FXR agonists - is that the question?","volume":"66","author":"Verbeke","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2022.06.013_bib19","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodeling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.013_bib20","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2022.06.013_bib21","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.cld.2022.06.013_bib22","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/liv.14490","article-title":"A\u00a0novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction","volume":"40","author":"An","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib23","first-page":"746A","article-title":"Final data of the phase 2a INTREPID study with EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist","volume":"72","author":"Knowdley","year":"2020","journal-title":"Hepatology"},{"issue":"24","key":"10.1016\/j.cld.2022.06.013_bib24","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J\u00a0Med Chem"},{"issue":"3","key":"10.1016\/j.cld.2022.06.013_bib25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non-bile acid FXR agonist tropifexor (LJN452) in healthy volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cld.2022.06.013_bib26","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0168-8278(18)30426-4","article-title":"Early assessment of safety and efficacy of tropifexor, a potent non-bile acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing phase 2 study","volume":"68","author":"Schramm","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.06.013_bib27","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib28","first-page":"31A","article-title":"The Nonsteroidal farnesoid X receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (PBC): a phase 2, randomized, placebo-controlled trial","volume":"70","author":"Kowdley","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.013_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cld.2012.12.001","article-title":"Nuclear receptors as drug targets in cholestatic liver diseases","volume":"17","author":"Halilbasic","year":"2013","journal-title":"Clin Liver Dis"},{"issue":"35","key":"10.1016\/j.cld.2022.06.013_bib30","doi-asserted-by":"crossref","first-page":"32852","DOI":"10.1074\/jbc.M305361200","article-title":"Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme","volume":"278","author":"Barbier","year":"2003","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.cld.2022.06.013_bib31","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/hep.25919","article-title":"Liver X receptor \u03b2 and peroxisome proliferator-activated receptor \u03b4 regulate cholesterol transport in murine cholangiocytes","volume":"56","author":"Xia","year":"2012","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2022.06.013_bib32","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/liv.13880","article-title":"Novel and emerging therapies for cholestatic liver diseases","volume":"38","author":"Goldstein","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2022.06.013_bib33","series-title":"Clinical lipidology","first-page":"315","article-title":"Chapter 26 \u2013 fibrates. Ballantyne CM","author":"Jones","year":"2009"},{"year":"2009","first-page":"1","series-title":"xPharm: the comprehensive pharmacology reference","key":"10.1016\/j.cld.2022.06.013_bib34"},{"issue":"4","key":"10.1016\/j.cld.2022.06.013_bib35","first-page":"219","article-title":"Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy","volume":"13","author":"Han","year":"2012","journal-title":"J\u00a0Dig Dis"},{"issue":"8","key":"10.1016\/j.cld.2022.06.013_bib36","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis","volume":"97","author":"Ohira","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2022.06.013_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc Med J"},{"issue":"6","key":"10.1016\/j.cld.2022.06.013_bib38","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","article-title":"Fenofibrate for patients with asymptomatic primary biliary cirrhosis","volume":"10","author":"Dohmen","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.013_bib39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.cld.2022.06.013_bib40","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1440-1746.2011.06737.x","article-title":"Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid","volume":"26","author":"Takeuchi","year":"2011","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.013_bib41","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep.30552","article-title":"Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis","volume":"70","author":"Honda","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.013_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib44","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0168-8278(17)30442-7","article-title":"A\u00a02-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid (Bezurso)","volume":"66","author":"Corpechot","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2022.06.013_bib45","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.cld.2022.06.013_bib46","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.14309\/ajg.0000000000001343","article-title":"Obeticholic acid and fibrates in primary biliary cholangitis: comparative effects in a multicentric observational study","volume":"116","author":"Reig","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2022.06.013_bib47","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1016\/S0168-8278(20)31411-2","article-title":"Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study","volume":"73","author":"Levy","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"S1","key":"10.1016\/j.cld.2022.06.013_bib48","first-page":"71","article-title":"Long-term safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC): 2-year results from a long-term study","volume":"74","author":"Mayo","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.15039","article-title":"Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis","volume":"42","author":"Kremer","year":"2022","journal-title":"Liver Int"},{"issue":"2 Suppl 3","key":"10.1016\/j.cld.2022.06.013_bib50","first-page":"5","article-title":"ENHANCE: safety and efficacy of seladelpar in patients with primary biliary cholangitis-A phase 3, international, randomized, placebo-controlled study","volume":"17","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"6","key":"10.1016\/j.cld.2022.06.013_bib51","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A\u00a0randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2022.06.013_bib53","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/17425255.4.7.895","article-title":"The pregnane X receptor: from bench to bedside","volume":"4","author":"Ma","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4\u20135","key":"10.1016\/j.cld.2022.06.013_bib54","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ejps.2008.12.007","article-title":"PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide","volume":"36","author":"Zimmermann","year":"2009","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib55","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.013_bib56","first-page":"695","article-title":"Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells","volume":"118","author":"Arenas","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.cld.2022.06.013_bib57","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.013_bib58","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A\u00a0placebo-controlled randomized trial of budesonide for PBC following an insufficient response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib59","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/pr.110.002980","article-title":"NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair","volume":"63","author":"Jiang","year":"2011","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.cld.2022.06.013_bib60","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.21093","article-title":"Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in\u00a0vivo","volume":"43","author":"Zhan","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2022.06.013_bib61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jhep.2019.04.012","article-title":"Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice","volume":"71","author":"Nishio","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.06.013_bib62","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/hep.25938","article-title":"Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent","volume":"56","author":"Aoyama","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.013_bib63","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/S0618-8278(19)30002-7","article-title":"Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: interim efficacy results of a phase 2 clinical trial","volume":"70","author":"Dalekos","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"S1","key":"10.1016\/j.cld.2022.06.013_bib64","first-page":"782A","article-title":"Setanaxib reduces cholestasis and fatigue in patients with primary biliary cholangitis and liver stiffness \u22659.6 kpa: post-hoc analyses from a randomized, controlled, phase 2 trial","volume":"74","author":"Levy","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2022.06.013_bib65","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A\u00a0mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.cld.2022.06.013_bib66","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.cld.2022.06.013_bib67","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.06.013_bib68","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.013_bib69","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2019.04.005","article-title":"Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature","volume":"101","author":"Bowlus","year":"2019","journal-title":"J\u00a0Autoimmun"},{"issue":"3","key":"10.1016\/j.cld.2022.06.013_bib70","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.06.013_bib71","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-642-14541-4_4","article-title":"Role of the intestinal bile acid transporters in bile acid and drug disposition","volume":"201","author":"Dawson","year":"2011","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"10.1016\/j.cld.2022.06.013_bib72","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A\u00a0randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis","volume":"3","author":"Mayo","year":"2019","journal-title":"Hepatol Commun"},{"issue":"10074","key":"10.1016\/j.cld.2022.06.013_bib73","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomized, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"issue":"2 Suppl 3","key":"10.1016\/j.cld.2022.06.013_bib74","first-page":"11","article-title":"GLIMMER trial-a randomized, double-blind, placebo-controlled study of linerixibat, an inhibitor of the ileal bile acid transporter, in the treatment of cholestatic pruritus in primary biliary cholangitis","volume":"17","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"3","key":"10.1016\/j.cld.2022.06.013_bib75","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"KALM-1 trial investigators. a phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N\u00a0Engl J Med"},{"year":"2018","author":"Khanna","series-title":"Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomized controlled trial","key":"10.1016\/j.cld.2022.06.013_bib76"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib77","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/13543784.7.1.99","article-title":"Modafinil: a novel stimulant for the treatment of narcolepsy","volume":"7","author":"Scammell","year":"1998","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib78","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.21230","article-title":"Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence","volume":"44","author":"Newton","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.06.013_bib79","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MJT.0000000000000387","article-title":"A\u00a0randomized, placebo-controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis","volume":"24","author":"Silveira","year":"2017","journal-title":"Am J Ther"},{"issue":"10","key":"10.1016\/j.cld.2022.06.013_bib80","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1007\/s10620-008-0613-3","article-title":"Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience","volume":"54","author":"Ian Gan","year":"2009","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.cld.2022.06.013_bib81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/bmb\/ldab005","article-title":"Mindfulness-based interventions: an overall review","volume":"138","author":"Zhang","year":"2021","journal-title":"Br Med Bull"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:00:28Z","timestamp":1761069628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326122000514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1089326122000514"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2022.06.013","relation":{},"ISSN":["1089-3261"],"issn-type":[{"type":"print","value":"1089-3261"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapies in Primary Biliary Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2022.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}